Literature DB >> 1425876

Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditions.

R A van Hogezand1, H M Kennis, A van Schaik, J P Koopman, P A van Hees, J H van Tongeren.   

Abstract

After oral administration of 5-aminosalicylic acid a substantial proportion of the acetylated form is excreted in the faeces. We have studied the role of the faecal microflora in acetylating 5-aminosalicylic acid. In faeces incubated under both aerobic and anaerobic conditions there was acetylation of 5-aminosalicylic acid. Of the anaerobic bacteria isolated from a 10(8) faecal dilution 44% were able to acetylate 5-aminosalicylic acid. We conclude that the normal faecal microflora contribute to the acetylation of 5-aminosalicylic acid.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1425876     DOI： 10.1007/bf01740669

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  18 in total

1.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

2.  Role of the intestinal flora in the acetylation of sulfasalazine metabolites.

Authors:  B J Dull; K Salata; P Goldman
Journal:  Biochem Pharmacol       Date:  1987-11-01       Impact factor: 5.858

3.  Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.

Authors:  A Shafii; J R Chowdhury; K M Das
Journal:  Am J Gastroenterol       Date:  1982-05       Impact factor: 10.864

4.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

Authors:  S N Rasmussen; S Bondesen; E F Hvidberg; S H Hansen; V Binder; S Halskov; H Flachs
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

5.  Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.

Authors:  K Lauritsen; J Hansen; M Ryde; J Rask-Madsen
Journal:  Gastroenterology       Date:  1984-06       Impact factor: 22.682

6.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

7.  Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.

Authors:  H J Pieniaszek; T R Bates
Journal:  J Pharm Sci       Date:  1979-10       Impact factor: 3.534

8.  The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis.

Authors:  C P Willoughby; J Piris; S C Truelove
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

9.  A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.

Authors:  U Klotz; K E Maier; C Fischer; K H Bauer
Journal:  Arzneimittelforschung       Date:  1985

10.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335
View more
  11 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Authors:  Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

Review 3.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

Review 4.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

5.  Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

Authors:  F N Hussain; R A Ajjan; S A Riley
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

6.  The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation.

Authors:  Jan-Ulrik Dahl; Michael J Gray; Daphne Bazopoulou; Francois Beaufay; Justine Lempart; Mark J Koenigsknecht; Ying Wang; Jason R Baker; William L Hasler; Vincent B Young; Duxin Sun; Ursula Jakob
Journal:  Nat Microbiol       Date:  2017-01-23       Impact factor: 17.745

7.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

8.  The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.

Authors:  E M Ryde; N O Ahnfelt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  Chemical transformation of xenobiotics by the human gut microbiota.

Authors:  Nitzan Koppel; Vayu Maini Rekdal; Emily P Balskus
Journal:  Science       Date:  2017-06-23       Impact factor: 47.728

Review 10.  Psychotropics and the Microbiome: a Chamber of Secrets….

Authors:  Sofia Cussotto; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.